Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | MAOA | P21397 | 1/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.77 |
| ▸ | F10 | P00742 | 1/20 | 0.67 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TOP1 | P11387 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11290551 | 0.99 | PDE3B (0.76) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL8264680 | 0.91 | PDE3B (0.64) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Hydrochloric Acid SCHEMBL7322526 | 0.90 | PDE3B (0.63) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL10769323 | 0.90 | PDE3B (0.72) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL9781456 | 0.89 | PDE3B (0.77) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL7714090 | 0.88 | PDE3B (0.73) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Pimobendan SCHEMBL1649737 | 0.87 | PDE3B (1.00) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL10460685 | 0.84 | PDE3B (0.70) | PDE3BPDE3AABCB11MAOAADORA2A | |
| Hydrochloric Acid SCHEMBL10463324 | 0.83 | PDE3B (0.68) | PDE3BPDE3AABCB11MAOAADORA2A | |
| SCHEMBL9781429 | 0.83 | PDE3B (0.68) | PDE3BPDE3AABCB11MAOAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6110471-A | ADMINISTERING PHOSPHODIESTERASE FOR INHIBITION OF THE CYCLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-08-29 | — | — | US | claimed |
| EP-0330052-B1 | Use of benzimidazoles for preparing a medicine with an anti-ischemial activity on the heart, and combinations with betablockers or bradycardics | THOMAE GMBH DR K (DE) | 1993-12-15 | — | — | EP | claimed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2023-10-26 | — | — | US | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| EP-0330052-B1 | Use of benzimidazoles for preparing a medicine with an anti-ischemial activity on the heart, and combinations with betablockers or bradycardics | THOMAE GMBH DR K (DE) | 1993-12-15 | — | — | EP | disclosed |
| EP-0387762-A2 | Medicament with positive inotropic activity, containing a synergistically active mixture consisting of a benzimidazole and a beta-blocker, its preparation and use | Dr. Karl Thomae GmbH (DE) | 1990-09-19 | — | — | EP | disclosed |
| EP-0330052-A2 | Use of benzimidazoles for preparing a medicine with an anti-ischemial activity on the heart, and combinations with betablockers or bradycardics | Dr. Karl Thomae GmbH (DE) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | PDE3B 5/4885PDE3A 6/4885ABCB11 4015/4885 |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | PDE3B 5/4885PDE3A 6/4885ABCB11 4015/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | PDE3B 5/4885PDE3A 6/4885ABCB11 4015/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | PDE3B 5/4885PDE3A 6/4885ABCB11 4015/4885 |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | PDE3B 5/4885PDE3A 6/4885ABCB11 4015/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | PDE3B 5/4885PDE3A 6/4885ABCB11 4015/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | PDE3B 5/4885PDE3A 6/4885ABCB11 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.